Clearmind Medicine published U.S. Patent applications covering combinations of LSD, ketamine and ibogaine with N-acylethanolamines. The applications address potential uses in depression, PTSD, pain and substance use disorders, giving investors a defined expansion of the company’s intellectual-property portfolio while patent outcomes remain uncertain.

Key Highlights

  • Clearmind Medicine’s U.S. patent applications were published on September 23, 2026.
  • The intellectual-property work is connected to collaboration with NeuroThera Labs Inc..
  • Clearmind said its approach is intended to pursue therapeutic effects at lower doses while preserving efficacy.

The company expanded its U.S. intellectual-property position by publishing patent applications covering combinations of LSD, ketamine and ibogaine with N-acylethanolamines. The applications address potential therapeutic uses in mental health disorders, pain and substance use disorders.

U.S. Applications Cover Psychedelic Combinations

The proposed combinations include N-acylethanolamines such as palmitoylethanolamide, or PEA. Potential areas identified include depression, post-traumatic stress disorder, pain and substance use disorders. Clearmind (NASDAQ: CMND) said its approach is intended to pursue therapeutic effects at lower doses while preserving efficacy, although it cautioned that a pending application may not result in an issued patent or a form advantageous to the company.